nach oben

Erschienen in:

28.03.2017 | Review

Androgenetic alopecia: a review

verfasst von: Francesca Lolli, Francesco Pallotti, Alfredo Rossi, Maria C. Fortuna, Gemma Caro, Andrea Lenzi, Andrea Sansone, Francesco Lombardo

Erschienen in: Endocrine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Androgenetic alopecia, commonly known as male pattern baldness, is the most common type of progressive hair loss disorder in men. The aim of this paper is to review recent advances in understanding the pathophysiology and molecular mechanism of androgenetic alopecia.

Methods

Using the PubMed database, we conducted a systematic review of the literature, selecting studies published from 1916 to 2016.

Results

The occurrence and development of androgenetic alopecia depends on the interaction of endocrine factors and genetic predisposition. Androgenetic alopecia is characterized by progressive hair follicular miniaturization, caused by the actions of androgens on the epithelial cells of genetically susceptible hair follicles in androgen-dependent areas. Although the exact pathogenesis of androgenetic alopecia remains to be clarified, research has shown that it is a polygenetic condition. Numerous studies have unequivocally identified two major genetic risk loci for androgenetic alopecia, on the X-chromosome AR⁄EDA2R locus and the chromosome 20p11 locus.

Conclusions

Candidate gene and genome-wide association studies have reported that single-nucleotide polymorphisms at different genomic loci are associated with androgenetic alopecia development. A number of genes determine the predisposition for androgenetic alopecia in a polygenic fashion. However, further studies are needed before the specific genetic factors of this polygenic condition can be fully explained.

J.B. Hamilton, Patterned loss of hair in man; types and incidence. Ann. N. Y. Acad. Sci. 53, 708–728 (1951)PubMed

L. Yip, S. Zaloumis, D. Irwin, G. Severi, J. Hopper, G. Giles, S. Harrap, R. Sinclair, J. Ellis, Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br. J. Dermatol. 161, 289–294 (2009)PubMed

G. Severi, R. Sinclair, J.L. Hopper, D.R. English, M.R.E. McCredie, P. Boyle, G.G. Giles, Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br. J. Dermatol. 149, 1207–1213 (2003)PubMed

N. Otberg, A.M. Finner, J. Shapiro, Androgenetic alopecia. Endocrinol. Metab. Clin. N. Am. 36, 379–398 (2007)

R. Paus, G. Cotsarelis, The biology of hair follicles. N. Engl. J. Med. 341, 491–497 (1999)PubMed

C. Pierard-Franchimont, G.E. Pierard, Teloptosis, a turning point in hair shedding biorhythms. Dermatology 203, 115–117 (2001)PubMed

W.C. Chumlea, T. Rhodes, C.J. Girman, A. Johnson-Levonas, F.R.W. Lilly, R. Wu, S.S. Guo, Family history and risk of hair loss. Dermatology 209, 33–39 (2004)PubMed

D. Osborn, Inheritance of baldness. Various patterns due to heredity and sometimes present at birth—a sex-limited character-dominant in man–women not bald unless they inherit tendency from both parents. J. Hered. 7, 347–355 (1916)

W. Kuster, R. Happle, The inheritance of common baldness: two B or not two B ? J. Am. Acad. Dermatol. 11, 921–926 (1984)PubMed

10.

E. Levy-Nissenbaum, M. Bar-Natan, M. Frydman, E. Pras, Confirmation of the association between male pattern baldness and the androgen receptor gene. Eur. J. Dermatol. 15, 339–340 (2005)PubMed

11.

C.C. Zouboulis, K. Degitz, Androgen action on human skin—from basic research to clinical significance. Exp. Dermatol. 13, 5–10 (2004)PubMed

12.

K.S. Stenn, R. Paus, T. Dutton, B. Sarba, Glucocorticoid effect on hair growth initiation: a reconsideration. Skin Pharmacol. 6, 125–134 (1993)PubMed

13.

D. Deplewski, R.L. Rosenfield, Role of hormones in pilosebaceous unit development. Endocr. Rev. 21, 363–392 (2000)PubMed

14.

C. Roh, Q. Tao, S. Lyle, Dermal papilla-induced hair differentiation of adult epithelial stem cells from human skin. Physiol. Genom. 19, 207–217 (2004)

15.

C. Blanpain, W.E. Lowry, A. Geoghegan, L. Polak, E. Fuchs, Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell 118, 635–648 (2004)PubMed

16.

V. Randall, in Hair and its Disorders: Biology, Pathology and Management, ed. By F. Camacho, V.A. Randall, P.V. The biology of androgenetic alopecia (Martin Dunitz, London, 2000), pp. 123–136

17.

A.J. Reynolds, R.F. Oliver, C.A. Jahoda, Dermal cell populations show variable competence in epidermal cell support: stimulatory effects of hair papilla cells. J. Cell Sci. 98(Pt 1), 75–83 (1991)PubMed

18.

N.A. Hibberts, A.E. Howell, V.A. Randall, Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J. Endocrinol. 156, 59–65 (1998)PubMed

19.

V.A. Botchkarev, J. Kishimoto, Molecular control of epithelial-mesenchymal interactions during hair follicle cycling. in Journal of Investigative Dermatology Symposium Proceedings. pp 46–55 (2003)

20.

V.A. Randall, M.J. Thornton, A.G. Messenger, Cultured dermal papilla cells from androgen-dependent human hair follicles (e.g. beard) contain more androgen receptors than those from non-balding areas of scalp. J. Endocrinol. 133, 141–147 (1992)PubMed

21.

S. Itami, S. Kurata, S. Takayasu, Androgen induction of follicular epithelial cell growth is mediated via insulin-like growth factor-I from dermal papilla cells. Biochem. Biophys. Res. Commun. 212, 988–994 (1995)PubMed

22.

S. Inui, Y. Fukuzato, T. Nakajima, K. Yoshikawa, S. Itami, Identification of androgen-inducible TGF-beta1 derived from dermal papilla cells as a key mediator in Androgenetic alopecia. J Investig. Dermatol. Symp. Proc. 8, 69–71 (2003)

23.

M. Philpott, in Hair and its Disorders: Biology, Research and Management. ed. By F. Camacho, lV. Randal, V. Price. The roles of growth factors in hair follicles: investigations using cultured hair follicles (Martin Dunitz, London, 2001) pp. 103–113

24.

R.D. Sinclair, Male androgenetic alopecia (Part II). J. Men’s Health Gend. 2, 38–44 (2005)

25.

S. Inui, Y. Fukuzato, T. Nakajima, K. Yoshikawa, S. Itami, Androgen-inducible TGF-beta1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understand paradoxical effects of androgen on human hair growth. FASEB J. 16, 1967–1969 (2002)PubMed

26.

S. Inui, S. Itami, Molecular basis of androgenetic alopecia: from androgen to paracrine mediators through dermal papilla. J. Dermatol. Sci. 61, 1–6 (2011)PubMed

27.

T. Hibino, T. Nishiyama, Role of TGF-beta2 in the human hair cycle. J. Dermatol. Sci. 35, 9–18 (2004)PubMed

28.

M.H. Kwack, Y.K. Sung, E.J. Chung, S.U. Im, J.S. Ahn, M.K. Kim, J.C. Kim, Dihydrotestosterone-inducible dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes. J. Invest. Dermatol. 128, 262–269 (2008)PubMed

29.

M.H. Kwack, J.S. Ahn, M.K. Kim, J.C. Kim, Y.K. Sung, Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice. J. Invest. Dermatol. 132, 43–49 (2012)PubMed

30.

V. Poor, S. Juricskay, E. Telegdy, Urinary steroids in men with male-pattern alopecia. J. Biochem. Biophys. Methods 53, 123–130 (2002)PubMed

31.

C.C. Zouboulis, The human skin as a hormone target and an endocrine gland. Hormones 3, 9–26 (2004)PubMed

32.

M. Fritsch, C.E. Orfanos, C.C. Zouboulis, Sebocytes are the key regulators of androgen homeostasis in human skin. J. Invest. Dermatol. 116, 793–800 (2001)PubMed

33.

L. Di Luigi, F. Romanelli, A. Lenzi, Androgenic-anabolic steroids abuse in males. J. Endocrinol. Invest. 28, 81–84 (2005)PubMed

34.

S. Inui, S. Itami, Androgen actions on the human hair follicle: perspectives. Exp. Dermatol. 22, 168–171 (2013)PubMed

35.

R. Hoffmann, Enzymology of the hair follicle. Eur. J. Dermatol. 11, 296–300 (2001)PubMed

36.

U. Hoppe, P.-M. Holterhus, L. Wunsch, D. Jocham, T. Drechsler, S. Thiele, C. Marschke, O. Hiort, Tissue-specific transcription profiles of sex steroid biosynthesis enzymes and the androgen receptor. J. Mol. Med. 84, 651–659 (2006)PubMed

37.

D. Thiboutot, P. Martin, L. Volikos, K. Gilliland, Oxidative activity of the type 2 isozyme of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) predominates in human sebaceous glands. J. Invest. Dermatol. 111, 390–395 (1998)PubMed

38.

S. Takayasu, Metabolism and action of androgen in the skin. Int. J. Dermatol. 18, 681–692 (1979)PubMed

39.

D.W. Russell, D.M. Berman, J.T. Bryant, K.M. Cala, D.L. Davis, C.P. Landrum, J.S. Prihoda, R.I. Silver, A.E. Thigpen, W.C. Wigley, The molecular genetics of steroid 5 alpha-reductases. Recent Prog. Horm. Res. 49, 275–284 (1994)PubMed

40.

S. Nakanishi, I. Adachi, K. Takayasu. in Hair Research for the Next Millennium. ed. By D. Neste. Expression of androgen receptor, type I and type II 5a-reductase in human dermal papilla cellse (VREPB, Amsterdam, 1996) pp 333–337

41.

Y. Asada, T. Sonoda, M. Ojiro, S. Kurata, T. Sato, T. Ezaki, S. Takayasu, 5 alpha-reductase type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro. J. Clin. Endocrinol. Metab. 86, 2875–2880 (2001)PubMed

42.

M.E. Sawaya, V.H. Price, Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J. Invest. Dermatol. 109, 296–300 (1997)PubMed

43.

M.E. Sawaya, N.S. Penneys, Immunohistochemical distribution of aromatase and 3B-hydroxysteroid dehydrogenase in human hair follicle and sebaceous gland. J. Cutan. Pathol. 19, 309–314 (1992)PubMed

44.

U. Ohnemus, M. Uenalan, J. Inzunza, J.-A. Gustafsson, R. Paus, The hair follicle as an estrogen target and source. Endocr. Rev. 27, 677–706 (2006)PubMed

45.

V.A. Randall, Role of 5α-reductase in health and disease, Baillière’s Clinical Endocrinology and Metabolism. 8(2), 405–431 (1994). doi:10.1016/S0950-351X(05)80259-9.CrossRef

46.

D. Gianfrilli, S. Pierotti, R. Pofi, C. Leonardo, M. Ciccariello, F. Barbagallo, Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology. Biomed. Res. Int. 2014, 464869 (2014)PubMedPubMedCentral

47.

M.J. McPhaul, Androgen receptor mutations and androgen insensitivity. Mol. Cell. Endocrinol. 198, 61–67 (2002)PubMed

48.

J.D. Wilson, J.E. Griffin, D.W. Russell, Steroid 5 alpha-reductase 2 deficiency. Endocr. Rev. 14, 577–593 (1993)PubMed

49.

T. Liang, S. Hoyer, R. Yu, K. Soltani, A.L. Lorincz, R.A. Hiipakka, S. Liao, Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J. Invest. Dermatol. 100, 663–666 (1993)PubMed

50.

T. Tadokoro, S. Itami, K. Hosokawa, H. Terashi, S. Takayasu, Human genital melanocytes as androgen target cells. J. Invest. Dermatol. 109, 513–517 (1997)PubMed

51.

S. Itami, S. Kurata, T. Sonoda, S. Takayasu, Interaction between dermal papilla cells and follicular epithelial cells in vitro: effect of androgen. Br. J. Dermatol. 132, 527–532 (1995)PubMed

52.

S. Inui, S. Itami, H.J. Pan, C. Chang, Lack of androgen receptor transcriptional activity in human keratinocytes. J. Dermatol. Sci. 23, 87–92 (2000)PubMed

53.

J.E. Cobb, N.C. Wong, L.W. Yip, J. Martinick, R. Bosnich, R.D. Sinclair, J.M. Craig, R. Saffery, S.B. Harrap, J.A. Ellis, Evidence of increased DNA methylation of the androgen receptor gene in occipital hair follicles from men with androgenetic alopecia. Br. J. Dermatol. 165, 210–213 (2011)PubMed

54.

N. Fujimoto, S. Yeh, H.Y. Kang, S. Inui, H.C. Chang, A. Mizokami, C. Chang, Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem. 274, 8316–8321 (1999)PubMed

55.

S. Inui, Y. Fukuzato, T. Nakajima, S. Kurata, S. Itami, Androgen receptor co-activator Hic-5/ARA55 as a molecular regulator of androgen sensitivity in dermal papilla cells of human hair follicles. J. Invest. Dermatol. 127, 2302–2306 (2007)PubMed

56.

S. Itami, S. Kurata, S. Takayasu, 5 Alpha-reductase activity in cultured human dermal papilla cells from beard compared with reticular dermal fibroblasts. J. Invest. Dermatol. 94, 150–152 (1990)PubMed

57.

S. Itami, S. Kurata, T. Sonoda, S. Takayasu, Characterization of 5 alpha-reductase in cultured human dermal papilla cells from beard and occipital scalp hair. J. Invest. Dermatol. 96, 57–60 (1991)PubMed

58.

P. Lee, C.-C. Zhu, N.S. Sadick, A.H. Diwan, P.S. Zhang, J.S. Liu, V.G. Prieto, Expression of androgen receptor coactivator ARA70/ELE1 in androgenic alopecia. J. Cutan. Pathol. 32, 567–571 (2005)PubMed

59.

M.E. Sawaya, A.R. Shalita, Androgen receptor polymorphisms (CAG repeat lengths) in androgenetic alopecia, hirsutism, and acne. J. Cutan. Med. Surg. 3, 9–15 (1998)PubMed

60.

A.M. Hillmer, S. Hanneken, S. Ritzmann, T. Becker, J. Freudenberg, F.F. Brockschmidt, A. Flaquer, Y. Freudenberg-Hua, R.A. Jamra, C. Metzen, U. Heyn, N. Schweiger, R.C. Betz, B. Blaumeiser, J. Hampe, S. Schreiber, T.G. Schulze, H.C. Hennies, J. Schumacher, P. Propping, T. Ruzicka, S. Cichon, T.F. Wienker, R. Kruse, M.M. Nothen, Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am. J. Hum. Genet. 77, 140–148 (2005)PubMedPubMedCentral

61.

J.A. Ellis, M. Stebbing, S.B. Harrap, Polymorphism of the androgen receptor gene is associated with male pattern baldness. J. Invest. Dermatol. 116, 452–455 (2001)PubMed

62.

J.A. Ellis, K.J. Scurrah, J.E. Cobb, S.G. Zaloumis, A.E. Duncan, S.B. Harrap, Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. Hum. Genet. 121, 451–457 (2007)PubMed

63.

V.M. Hayes, G. Severi, Sa Eggleton, E.J.D. Padilla, M.C. Southey, R.L. Sutherland, J.L. Hopper, G.G. Giles, Short communication the E211 G > a androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol. 14, 993–996 (2005)

64.

J.E. Cobb, S.J. White, S.B. Harrap, J.A. Ellis, Androgen receptor copy number variation and androgenetic alopecia: a case-control study. PLoS One 4, e5081 (2009)PubMedPubMedCentral

65.

D.A. Prodi, N. Pirastu, G. Maninchedda, A. Sassu, A. Picciau, M.A. Palmas, A. Mossa, I. Persico, M. Adamo, A. Angius, M. Pirastu, EDA2R is associated with androgenetic alopecia. J. Invest. Dermatol. 128, 2268–2270 (2008)PubMed

66.

A.M. Hillmer, J. Freudenberg, S. Myles, S. Herms, K. Tang, D.A. Hughes, F.F. Brockschmidt, Y. Ruan, M. Stoneking, M.M. Nöthen, Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness. Hum. Genet. 126, 255 (2009)PubMedPubMedCentral

67.

F.F. Brockschmidt, A.M. Hillmer, S. Eigelshoven, S. Hanneken, S. Heilmann, S. Barth, C. Herold, T. Becker, R. Kruse, M.M. Nöthen, Fine mapping of the human AR/EDA2R locus in androgenetic alopecia. Br. J. Dermatol. 162, 899–903 (2010)PubMed

68.

J.A. Ellis, M. Stebbing, S.B. Harrap, Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J. Invest. Dermatol. 110, 849–853 (1998)PubMed

69.

J.B. Richards, X. Yuan, F. Geller, D. Waterworth, V. Bataille, D. Glass, K. Song, G. Waeber, P. Vollenweider, K.K.H. Aben, L.A. Kiemeney, B. Walters, N. Soranzo, U. Thorsteinsdottir, A. Kong, T. Rafnar, P. Deloukas, P. Sulem, H. Stefansson, K. Stefansson, T.D. Spector, V. Mooser, Male-pattern baldness susceptibility locus at 20p11. Nat. Genet. 40, 1282–1284 (2008)PubMedPubMedCentral

70.

F.F. Brockschmidt, S. Heilmann, J.A. Ellis, S. Eigelshoven, S. Hanneken, C. Herold, S. Moebus, M.A. Alblas, B. Lippke, N. Kluck, L. Priebe, F.A. Degenhardt, R.A. Jamra, C. Meesters, K.H. Jöckel, R. Erbel, S. Harrap, J. Schumacher, H. Fröhlich, R. Kruse, A.M. Hillmer, T. Becker, M.M. Nöthen, Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br. J. Dermatol. 165, 1293–1302 (2011)PubMed

71.

A.M. Hillmer, F.F. Brockschmidt, S. Hanneken, S. Eigelshoven, M. Steffens, A. Flaquer, S. Herms, T. Becker, A.-K. Kortüm, D.R. Nyholt, Z.Z. Zhao, G.W. Montgomery, N.G. Martin, T.W. Mühleisen, M.A. Alblas, S. Moebus, K.-H. Jöckel, M. Bröcker-Preuss, R. Erbel, R. Reinartz, R.C. Betz, S. Cichon, P. Propping, M.P. Baur, T.F. Wienker, R. Kruse, M.M. Nöthen, Susceptibility variants for male-pattern baldness on chromosome 20p11. Nat. Genet. 40, 1279–1281 (2008)PubMed

72.

D.R. Chesire, W.B. Isaacs, Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene 21, 8453–8469 (2002)PubMed

73.

R. Li, F.F. Brockschmidt, A.K. Kiefer, H. Stefansson, D.R. Nyholt, K. Song, S.H. Vermeulen, S. Kanoni, D. Glass, S.E. Medland, M. Dimitriou, D. Waterworth, J.Y. Tung, F. Geller, S. Heilmann, A.M. Hillmer, V. Bataille, S. Eigelshoven, S. Hanneken, S. Moebus, C. Herold, M. den Heijer, G.W. Montgomery, P. Deloukas, N. Eriksson, A.C. Heath, T. Becker, P. Sulem, M. Mangino, P. Vollenweider, T.D. Spector, G. Dedoussis, N.G. Martin, L.A. Kiemeney, V. Mooser, K. Stefansson, D.A. Hinds, M.M. Nöthen, J.B. Richards, Six novel susceptibility loci for early-onset androgenetic alopecia and their unexpected association with common diseases. PLoS Genet. 8, e1002746 (2012)PubMedPubMedCentral

74.

T. Kitagawa, K.I. Matsuda, S. Inui, H. Takenaka, N. Katoh, S. Itami, S. Kishimoto, M. Kawata, Keratinocyte growth inhibition through the modification of wnt signaling by androgen in balding dermal papilla cells. J. Clin. Endocrinol. Metab. 94, 1288–1294 (2009)PubMedPubMedCentral

75.

G.J. Leirõs, A.I. Attorresi, M.E. Balañá, Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br. J. Dermatol. 166, 1035–1042 (2012)PubMed

76.

J.S. Crabtree, E.J. Kilbourne, B.J. Peano, S. Chippari, T. Kenney, C. McNally, W. Wang, H.A. Harris, R.C. Winneker, S. Nagpal, C.C. Thompson, A mouse model of androgenetic alopecia. Endocrinology 151, 2373–2380 (2010)PubMed

77.

F. Yang, X. Li, M. Sharma, C.Y. Sasaki, D.L. Longo, B. Lim, Z. Sun, Linking beta-catenin to androgen-signaling pathway. J. Biol. Chem. 277, 11336–11344 (2002)PubMed

78.

J. Kishimoto, R.E. Burgeson, B.A. Morgan, Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev. 14, 1181–1185 (2000)PubMedPubMedCentral

79.

C. Lo Celso, D.M. Prowse, F.M. Watt, Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development 131, 1787–1799 (2004)PubMed

80.

D. Van Mater, F.T. Kolligs, A.A. Dlugosz, E.R. Fearon, Transient activation of beta -catenin signaling in cutaneous keratinocytes is sufficient to trigger the active growth phase of the hair cycle in mice. Genes Dev. 17, 1219–1224 (2003)PubMedPubMedCentral

81.

T. Andl, S.T. Reddy, T. Gaddapara, S.E. Millar, WNT signals are required for the initiation of hair follicle development. Dev. Cell 2, 643–653 (2002)PubMed

82.

A.A. Mills, B. Zheng, X.J. Wang, H. Vogel, D.R. Roop, A. Bradley, p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708–713 (1999)PubMed

83.

M. Sosnova, M. Bradl, J.V. Forrester, CD34+ corneal stromal cells are bone marrow-derived and express hemopoietic stem cell markers. Stem Cells 23, 507–515 (2005)PubMed

84.

L.A. Garza, Y. Liu, Z. Yang, B. Alagesan, J.A. Lawson, S.M. Norberg, D.E. Loy, T. Zhao, H.B. Blatt, D.C. Stanton, L. Carrasco, G. Ahluwalia, S.M. Fischer, G.A. FitzGerald, G. Cotsarelis, Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia 4, 126ra34 (2012).

85.

S. Heilmann, D.R. Nyholt, F.F. Brockschmidt, A.M. Hillmer, C. Herold, T. Becker, N.G. Martin, M.M. Nöthen, No genetic support for a contribution of prostaglandins to the aetiology of androgenetic alopecia. Br. J. Dermatol. 169, 222–224 (2013)PubMed

86.

A.W. Bahta, N. Farjo, B. Farjo, M.P. Philpott, Premature senescence of balding dermal papilla cells in vitro is associated with p16(INK4a) expression. J. Invest. Dermatol. 128, 1088–1094 (2008)PubMed

87.

Q.M. Chen, Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann. N. Y. Acad. Sci. 908, 111–125 (2000)PubMed

88.

J.H. Upton, R.F. Hannen, A.W. Bahta, N. Farjo, B. Farjo, M.P. Philpott, Oxidative stress–associated senescence in dermal papilla cells of men with androgenetic alopecia. J. Investig. Dermatol. Adv. Online Publ. 135, 1244–1252 (2015)

89.

M. Bienova, R. Kucerova, M. Fiuraskova, M. Hajduch, Z. Kolar, Androgenetic alopecia and current methods of treatment. Acta. Dermatovenerol. Alp. Pannonica Adriat. 14, 5–8 (2005)PubMed

90.

H.S. Shin, C.H. Won, S.H. Lee, O.S. Kwon, K.H. Kim, H.C. Eun, Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am. J. Clin. Dermatol. 8, 285–290 (2007)PubMed

91.

A.E. Buhl, D.J. Waldon, T.T. Kawabe, J.M. Holland, Minoxidil stimulates mouse vibrissae follicles in organ culture. J. Invest. Dermatol. 92, 315–320 (1989)PubMed

92.

A. Blumeyer, A. Tosti, A. Messenger, P. Reygagne, V. Del Marmol, P.I. Spuls, M. Trakatelli, A. Finner, F. Kiesewetter, R. Trüeb, B. Rzany, U. Blume-Peytavi, Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. JDDG 9, S1–S57 (2011)PubMed

93.

E.P. Jenkins, S. Andersson, J. Imperato-McGinley, J.D. Wilson, D.W. Russell, Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J. Clin. Invest. 89, 293–300 (1992)PubMedPubMedCentral

94.

D.W. Russell, J.D. Wilson, Steroid 5 alpha-reductase: two genes/two enzymes. Annu. Rev. Biochem. 63, 25–61 (1994)PubMed

95.

G. Harris, B. Azzolina, W. Baginsky, G. Cimis, G.H. Rasmusson, R.L. Tolman, C.R. Raetz, K. Ellsworth, Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp. Proc. Natl Acad. Sci. USA 89, 10787–10791 (1992)PubMed

96.

A.E. Thigpen, R.I. Silver, J.M. Guileyardo, M.L. Casey, J.D. McConnell, D.W. Russell, Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J. Clin. Invest. 92, 903–910 (1993)PubMedPubMedCentral

97.

E. Bayne, J. Flanagan, B. Azzolina, R. Einstein, J. Mumford, B. Avala, D. Chang, I. Thiboutot, I. Singer, G. Harris, Immunolocalization of type 2 5a-reductase in human hair follicles [abstract]. in 1997 Annual Meeting Society for Investigative Dermatology. p. 651 (1997)

98.

L. Drake, M. Hordinsky, V. Fiedler, J. Swinehart, W.P. Unger, P.C. Cotterill, D.M. Thiboutot, N. Lowe, C. Jacobson, D. Whiting, S. Stieglitz, S.J. Kraus, E.I. Griffin, D. Weiss, P. Carrington, C. Gencheff, G.W. Cole, D.M. Pariser, E.S. Epstein, W. Tanaka, A. Dallob, K. Vandormael, L. Geissler, J. Waldstreicher, The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J. Am. Acad. Dermatol. 41, 550–554 (1999)PubMed

99.

M. Caserini, M. Radicioni, C. Leuratti, E. Terragni, M. Iorizzo, R. Palmieri, Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int. J. Clin. Pharmacol. Ther. 54, 19–27 (2016)PubMed

100.

M. Caserini, M. Radicioni, C. Leuratti, O. Annoni, R. Palmieri, A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. 52, 842–849 (2014)PubMed

101.

B.S. Chandrashekar, T. Nandhini, V. Vasanth, R. Sriram, S. Navale, Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride. Indian Dermatol. Online J. 6, 17–20 (2015)PubMedPubMedCentral

102.

Z. Hajheydari, J. Akbari, M. Saeedi, L. Shokoohi, Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J. Dermatol. Venereol. Leprol. 75, 47–51 (2009)PubMed

103.

C. Tanglertsampan, Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J. Med. Assoc. Thail. 95, 1312–1316 (2012)

104.

S. Khandpur, M. Suman, B.S. Reddy, Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J. Dermatol. 29, 489–498 (2002)PubMed

105.

A.R. Diani, M.J. Mulholland, K.L. Shull, M.F. Kubicek, G.A. Johnson, H.J. Schostarez, M.N. Brunden, A.E. Buhl, Hair growth effects of oral administration of finasteride, a steroid 5α-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J. Clin. Endocrinol. Metab. 74, 345–350 (1992)PubMed

106.

A. Rossi, C. Cantisani, M. Scarno, A. Trucchia, M.C. Fortuna, S. Calvieri, Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol. Ther. 24, 455–461 (2011)PubMed

107.

J.W. Overstreet, V.L. Fuh, J. Gould, S.S. Howards, M.M. Lieber, W. Hellstrom, S. Shapiro, P. Carroll, R.S. Corfman, S. Petrou, R. Lewis, P. Toth, T. Shown, J. Roy, J.P. Jarow, J. Bonilla, C.A. Jacobsen, D.Z. Wang, K.D. Kaufman, Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J. Urol. 162, 1295–1300 (1999)PubMed

108.

A.M. Traish, J. Hassani, A.T. Guay, M. Zitzmann, M.L. Hansen, Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J. Sex. Med. 8, 872–884 (2011)PubMed

109.

M.S. Irwig, S. Kolukula. Persistent sexual side effects of finasteride for male pattern hair loss. J. Sex. Med. 8, 1747–1753 (2011)PubMed

110.

Y. Wu, R.R. Chhipa, H. Zhang, C. Ip, The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol. Ther. 11, 902–909 (2011)PubMedPubMedCentral

111.

D.A. Finn, S.L. Long, M.A. Tanchuck, J.C. Crabbe, Interaction of chronic ethanol exposure and finasteride: sex and strain differences. Pharmacol. Biochem. Behav. 78, 435–443 (2004)PubMed

112.

B. Stoffel-Wagner, Neurosteroid biosynthesis in the human brain and its clinical implications. Ann. N. Y. Acad. Sci. 1007, 64–78 (2003)PubMed

113.

R. Rupprecht, F. Holsboer, Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 22, 410–416 (1999)PubMed

Titel: Androgenetic alopecia: a review
verfasst von: Francesca Lolli
Francesco Pallotti
Alfredo Rossi
Maria C. Fortuna
Gemma Caro
Andrea Lenzi
Andrea Sansone
Francesco Lombardo
Publikationsdatum: 28.03.2017
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-017-1280-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial

Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability

Resection of tumors of the third ventricle involving the hypothalamus: effects on body mass index using a dedicated surgical approach

Performance of low-dose cosyntropin stimulation test handled via plastic tube

Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice